1. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. (December 2016) Authors: Massard, C.; Soria, J.C.; Stathis, A.; Delord, J.P.; Awada, A.; Peters, S.; Lewin, J.; Bekradda, M.; Rezai, K.; Zeng, Z.; Azher, H.; Perez, S.; Siu, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (8th March 2016) Authors: Gaudio, E.; Tarantelli, C.; Kwee, I.; Barassi, C.; Bernasconi, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Targa, A.; Stathis, A.; Goodstal, S.; Zucca, E.; Bertoni, F. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors. (December 2016) Authors: Aoyama, T.; Fasolo, A.; Stathis, A.; Sessa, C.; Hollebecque, A.; Soria, J.C.; Pastorino, A.; Alberto Sobrero, A.S.; Van Laethem, J.L.; Saito, K.; Yoshida, K.; Winkler, R.; Benedetti, F.; Gianni, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models. (December 2016) Authors: Gaudio, E.; Tarantelli, C.; Spriano, F.; Bernasconi, E.; Targa, A.; Dirnhofer, S.; Stathis, A.; Zucca, E.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. (December 2016) Authors: Tarantelli, C.; Gaudio, E.; Hillmann, P.; Spriano, F.; Rinaldi, A.; Kwee, I.; Cascione, L.; Fabbro, D.; Stathis, A.; Zucca, E.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗